Retosiban

CAS : 820957-38-8

Ref. 3D-VHB95738

Informations sur le produit

• Nom: Retosiban
• Synonymes: (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-((1S)-1-methylpropyl)-2,5-piperazinedione, Morpholine, 4-[(2R)-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1S)-1-methylpropyl]-2,5-dioxo-1-piperazinyl](2-methyl-4-oxazolyl)acetyl]-, 2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)-, (3R,6R)-3-(2,3-Dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione

Description

Retosiban is a crystalline polymorph of atosiban, which is a cyclic peptidyl oxytocin receptor agonist. It has been shown to inhibit the release of oxytocin in human myometrial cells and can be used for the treatment of uterine contractions. Retosiban also has an inhibitory effect on the production of prostaglandins and collagenase activity, suggesting that it may have therapeutic potential in the treatment of cancer and autoimmune diseases.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 494.6 g/mol
• Formule: C₂₇H₃₄N₄O₅
• Degré de pureté: Min. 95%